A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.

A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.

Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.

Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.

Fezolinetant (Veozah) was linked to objective and patient-reported sleep gains in OPTION-VMS, with no new safety signals observed.

Wen Shen, MD, explains how clinicians can counter menopause misinformation from social media and steer patients toward evidence-based resources.